Can stem cells help heal a broken heart? new study investigates

NCT ID NCT07604467

Recruiting now Knowledge-focused Sponsor: University Medical Centre Ljubljana Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether CD34+ stem cells, which help maintain tiny blood vessels in the heart, are linked to how well the heart recovers in people with Takotsubo syndrome (also known as broken heart syndrome). Researchers will measure heart function in 40 participants at the start and after 6 months. The goal is to better understand the role of these stem cells in heart recovery, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD34+ stem cells
What this could lead to: If successful, this could point toward a way to predict or improve heart recovery in people with Takotsubo syndrome.
What could go wrong: This is a small, early observational study, not a treatment trial. It may not lead to any new therapy, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC CONTRACTILITY RECOVERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary microvascular disorder heart failure Tako-tsubo cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC CONTRACTILITY RECOVERY CD34+ STEM CELLS HEART FAILURE MICROVASCULAR DYSFUNCTION TAKO-TSUBO CARDIOMYOPATHY

Contacts and locations

Locations

Advanced Heart Failure and Transplantation Program, Department of Cardiology, UMC Ljubljana, Slovenia
RECRUITING

Ljubljana, Ljubljana, 1000, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.